| Company/Division name | Moderna Therapeutics |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Kept from Offshoring |
| Total number of jobs (added or to be added): | 125 |
| Year reshoring announced: | 2016 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 150 |
| City reshored to: | Cambridge |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Loss of control, No Flexibility |
| What domestic positive factors made reshoring more attractive? | Customization/Flexibility, Eco-system synergies, Skilled workforce availability/training |
